Evidence-based decision making about Hib vaccination
Abstract
In response to the results of the Lombok Haemophilus influenzae type b (Hib) vaccine probe trial (Jan 1, p 43),1 Ana Lucia Sgambatti de Andrade and Celina Turchi Martelli (p 5)2 ask “How much evidence is sufficient for policy makers?” In July, 2004, the Global Alliance for Vaccines and Immunization (GAVI) established a Task Force to explore how countries can be supported to make evidence-based decisions on the introduction and continued use of Hib-containing vaccines. Since then, the Task Force has undertaken a country consultation process, and explored issues related to programmes, supply, and financing associated with Hib vaccination in three groups of countries: those that have or are about to introduce Hib vaccine (Kenya, Ghana, Malaysia, Mongolia); those that are eligible for Hib but have not applied (Cameroon, Mozambique); and those considered to have an unclear disease burden (Bangladesh, Uzbekistan).
Citation
Lancet(2005) 365 (9463) 936-937 [doi:10.1016/S0140-6736(05)71076-X]